Description
Sotakras 120 mg contains Sotrasiv, a groundbreaking oral targeted therapy for the treatment of non-small cell lung cancer (NSCLC). Sotrasiv is a KRAS-G12C inhibitor and has shown significant efficacy in patients with germ-type tumors. It was developed by Amgen and sold under the brand name Lumakras in some regions.
The structure and mechanism of action
Each Sotakura 120 mg tablet contains sotrasiv, a selective and irreversible inhibitor of the KRAS-G12C mutation that occurs in approximately 13% of NSCLC cases. KRAS is a carcinogen that plays an important role in cell growth and survival. The G12C mutation leads to continuous activation of KRA, which leads to the unregulated proliferation of cancer cells.
Sotrasive binds to the inactive GDP-binding state of the KRAS-G12C mutant, blocking it into an inactive conformation, preventing downstream signaling. This targeting effect disrupts tumor growth and induces apoptosis (programmed cell death).
Indications
SOTAKRAS 120 mg is administered primarily for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received at least previous systemic therapy. It is prescribed as a second or later treatment option after chemotherapy or immunotherapy failure.
Dosage and administration
Recommended dosage: 960 mg (8 tablets of 120 mg). This was taken verbally once a day with or without food.
Whole Swallow: The tablets are completely swallow and do not need to be chew, crush or share.
Missed Dose: If the dose is overlook for more than 6 hours, the patient should skip the dose and take the next planned dose.
Side effects
Frequent side effects of Sotakras 120 mg include:
Gastrointestinal problems: diarrhea, nausea, vomiting, constipation
Liver function abnormality: Increased old branches and branches (liver enzymes)
Fatigue and weakness
Cough and difficulty breathing (short of breath)
Musculoskeletal pain
Warnings and Precautions
Liver Acidity: Regular monitoring of liver function tests is requir, and dose adjustments may be requir for serious increases.
Interstitial Lung Disease (ILD)/Pneumonia: Patients should monitor for new functions or degradation of respiratory symptoms.
Drug-to-drug interactions: Sotakura can interact with CYP3A4 inhibitors or inductors that can affect drug metabolism and efficacy.
Pregnancy and breastfeeding: The safety of sotrasive during pregnancy and breastfeeding has not been determin. Pregnant women should avoid using this medication as it may cause fetal damage.
Conclusion
Sotakras 120 mg (Sotorasib) is a promising targeted therapy for patients with KRAS G12C-muting NSCLC. It offers considerable advancements in precision cosandology and offers effective treatment options with only a few options. However, patients should be monitor carefully for side effects and abnormal liver function. Doctors should evaluate the risk-benefit profile before prescribing this medication.
How to order IEB Pharma medicine…
Ordering our IEB Pharma Medicines is easy. Currently there is no automated ordering system on our website; we offer various options for ordering IEB Pharma Medicines.
WhatsApp: You can send a message by clicking on our WhatsApp button, and a customer service representative of IEB Pharma will assist you in placing your order.
Telegram/Messenger/WeChat: If you want to place an order on our Facebook Messenger, Telegram, or WeChat, then you can easily place an order by clicking on our message option button.
Email: You can message us at [email protected] for details about your order. We answer your call as soon as we can.
